Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat.
Abstract
Constant release of the androgen 5 alpha-dihydrotestosterone (DHT) in ovariectomized rats bearing DMBA-induced mammary carcinoma caused a marked inhibition of tumor growth induced by 17 beta-estradiol (E2). That DHT acts through interaction with the androgen receptor is supported by the finding that simultaneous treatment with the antiandrogen Flutamide completely prevents DHT action. Particularly illustrative of the potent inhibitory effect of DHT on tumor growth are the decrease by DHT of the number of progressing tumors from 69.2% to 29.2% in E2-treated animals and the increase by DHT of the number of complete responses (disappearance of palpable tumors) from 11.5% to 33.3% in the same groups of animals. The number of new tumors appearing during the 28-day observation period in E2-treated animals decreased from 1.5 +/- 0.3 to 0.7 +/- 0.2 per rat during treatment with DHT, an effect which was also reversed by the antiandrogen Flutamide. The present data demonstrate, for the first time, that androgens are potent inhibitors of DMBA-induced mammary carcinoma growth by an action independent of inhibition of gonadotropin secretion, and suggest an action exerted directly at the tumor level.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Constant release of DHT in ovariectomized rats bearing DMBA-induced mammary carcinoma caused marked inhibition of tumor growth induced by E2.
“Dauvois et al. (242) have shown that constant release of the androgen DHT in ovariectomized rats bearing DMBA-induced mammary carcinoma caused a marked inhibition of tumor growth induced by E 2 (Fig. 21).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [242]
DHT acts through interaction with the AR in DMBA-induced mammary carcinoma.
“That DHT acts through interaction with the AR in DMBA-induced mammary carcinoma is well supported by the finding that simultaneous treatment with the antiandrogen flutamide completely prevented DHT action.”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [242]
Androgens are potent inhibitors of DMBA-induced mammary carcinoma growth by an action independent from inhibition of gonadotropin secretion.
“Such data demonstrated, for the first time, that androgens are potent inhibitors of DMBA-induced mammary carcinoma growth by an action independent from inhibition of gonadotropin secretion and suggested an action exerted directly at the tumor level, thus further supporting in vitro data obtained with the human ZR-75-1 breast cancer cell line (208,209).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [242]
DMBA-induced mammary carcinoma in the rat has been widely used as a model of hormone-sensitive breast cancer in women.
“The DMBA-induced mammary carcinoma in the rat has been widely used as a model of hormone-sensitive breast cancer in women (242,256,257).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [242]
Cites
Extension of Multiple Range Tests to Group Means with Unequal Numbers of Replications
Kramer, C. Y. (1956) · Biometrics · doi:10.2307/3001469 · Cited by 3,146 · see citing works
Practical Nonparametric Statistics
Obremski, T. E., & Conover, W. J. (1981) · Technometrics · doi:10.2307/1268234 · Cited by 1,429 · see citing works
Estrogen Receptors in Human Breast Cancer
Powles, T. J. (1976) · Journal of Clinical Pathology · doi:10.1136/jcp.29.5.467-d · Cited by 614 · see citing works
Welsch, C. W. (1985) · PubMed · Cited by 496 · see citing works
RAPID INDUCTION OF MAMMARY CARCINOMA IN THE RAT AND THE INFLUENCE OF HORMONES ON THE TUMORS
Huggins, C., Briziarelli, G., & Sutton, H. (1959) · The Journal of Experimental Medicine · doi:10.1084/jem.109.1.25 · Cited by 373 · see citing works
NERI, R. O., FLORANCE, K., Koziol, P., & CLEAVE, S. V. (1972) · Endocrinology · doi:10.1210/endo-91-2-427 · Cited by 326 · see citing works
Simard, J., Luthy, I., Guay, J., Bélanger, A., & Labrie, F. (1986) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(86)90132-2 · Cited by 256 · see citing works
Self-citationPoulin, R., Baker, D., & Labrie, F. (1988) · Breast Cancer Research and Treatment · doi:10.1007/bf01805942 · Cited by 172 · see citing works
Self-citationAndrogenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate.
LABRIE, C., BELANGER, A., & LABRIE, F. (1988) · Endocrinology · doi:10.1210/endo-123-3-1412 · Cited by 167 · see citing works
Self-citationRelationship of presence of progesterone receptors to prognosis in early breast cancer.
Pichon, M.-F., Pallud, C., Brunet, M., et al. (1980) · PubMed · Cited by 160 · see citing works
Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.
TORMEY, D. C., LIPPMAN, M. E., EDWARDS, B. K., & CASSIDY, J. G. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-2-139 · Cited by 128 · see citing works
Huggins, C., Jensen, E. V., & Cleveland, A. S. (1954) · The Journal of Experimental Medicine · doi:10.1084/jem.100.3.225 · Cited by 120 · see citing works
Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line.
POULIN, R., SIMARD, J., LABRIE, C., PETITCLERC, L., DUMONT, M., LAGACÉ, L., & LABRIE, F. (1989) · Endocrinology · doi:10.1210/endo-125-1-392 · Cited by 115 · see citing works
Self-citationTestosterone Propionate Therapy in Breast Cancer
(1964) · JAMA · doi:10.1001/jama.1964.03060380037009 · Cited by 114 · see citing works
The estrogenic and antiestrogenic activities of androgens in female target tissues.
Rochefort, H., & Garcia, M. (1983) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(83)90013-x · Cited by 107 · see citing works
Fluoxymesterone Therapy in Advanced Breast Cancer
Kennedy, B. J. (1958) · New England Journal of Medicine · doi:10.1056/nejm195810022591404 · Cited by 100 · see citing works
Androgen Action through Estrogen Receptor in a Human Breast Cancer Cell Line*
Zava, D. T., & McGuire, W. L. (1978) · Endocrinology · doi:10.1210/endo-103-2-624 · Cited by 91 · see citing works
Labrie, C., Cusan, L., Plante, M., Lapointe, S., & Labrie, F. (1987) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(87)91054-5 · Cited by 91 · see citing works
Self-citationLüthy, I. A., Begin, D. J., & Labrie, F. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90295-6 · Cited by 90 · see citing works
Self-citationHuman breast cancer: androgen action mediated by estrogen receptor.
Zava, D. T., & McGuire, W. L. (1978) · Science · doi:10.1126/science.622569 · Cited by 82 · see citing works
ASSELIN, J., KELLY, P. A., CARON, M. G., & LABRIE, F. (1977) · Endocrinology · doi:10.1210/endo-101-3-666 · Cited by 73 · cited 3× · see citing works
“In fact, the growth of DMBA-induced mammary tumors is highly sensitive to prolactin [17, 18, 49].”
BackgroundMethodSelf-citationSimard, J., Hatton, A. C., Labrief, C., Dauvois, S., Zhao, H. F., Haagensen, D. E., & Labrie, F. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-4-694 · Cited by 72 · see citing works
Self-citationSteroid metabolism by human breast and rat mammary carcihomata
Miller, W. R. (1974) · Steroids · doi:10.1016/0039-128x(74)90089-0 · Cited by 71 · see citing works
Dauvois, S., & Labrie, F. (1989) · Breast Cancer Research and Treatment · doi:10.1007/bf01806551 · Cited by 68 · see citing works
Self-citationIdentification and androgen regulation of two proteins released by T47D human breast cancer cells.
Chalbos, D., Haagensen, D. E., Parish, T., & Rochefort, H. (1987) · PubMed · Cited by 66 · see citing works
Garcia, M., & Rochefort, H. (1977) · Steroids · doi:10.1016/0039-128x(77)90114-3 · Cited by 59 · see citing works
Asselin, J., & Labrie, F. (1978) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(78)90035-3 · Cited by 57 · see citing works
Self-citationTreatment of Breast Cancer with Testosterone Propionate
Fels, E. (1944) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-4-3-121 · Cited by 56 · see citing works
Estrogen-prolactin dependency in 7,12-dimethylbenz(a)anthracene-induced tumors.
Leung, B. S., Sasaki, G. H., & Leung, J. S. (1975) · PubMed · Cited by 56 · see citing works
HORMONAL INFLUENCES ON MAMMARY TUMORS OF THE RAT
Huggins, C., & Mainzer, K. (1957) · The Journal of Experimental Medicine · doi:10.1084/jem.105.5.485 · Cited by 55 · see citing works
An Antiestrogenic Action of Androgens in Human Breast Cancer Cells*
MacIndoe, J. H., & Etre, L. A. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-53-4-836 · Cited by 54 · see citing works
Biologic characteristics and chemotherapy of 7,12-dimethylbenz[a]anthracene-induced tumors in rats.
Teller, M. N., Stock, C., Stohr, G., et al. (1966) · PubMed · Cited by 52 · see citing works
Specific binding of estradiol and dihydrotestosterone in human mammary cancers.
Trams, G., & Maass, H. (1977) · PubMed · Cited by 42 · see citing works
Asselin, J., Mélançon, R., Moachon, G., & Bélanger, A. (1980) · PubMed · Cited by 40 · see citing works
Costlow, M. E., Buschow, R. A., & McGuire, W. L. (1976) · PubMed · Cited by 32 · see citing works
Calusterone (7β,17α-DimethyItestosterone) as Primary and Secondary Therapy of Advanced Breast Cancer
Gordan, G. S., Halden, A., Horn, Y., Fuery, J. J., Parsons, R. J., & Walter, R. M. (2009) · Oncology · doi:10.1159/000224811 · Cited by 32 · cited 1× · see citing works
“Nevertheless, androgens such as testosterone propionate [3-5], fluoxymesterone [6, 7], and calusterone [ 8 ] have been used in the adjuvant therapy of breast cancer with an objective response comparable to that obtained with other endocrine therapies [1, 5, 9, 10].”
Garcia, M., & Rochefort, H. (1978) · PubMed · Cited by 31 · see citing works
Plante, M., Lapointe, S. P., & Labrie, F. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90206-3 · Cited by 31 · see citing works
Self-citationEstrogen receptors in androgen-induced breast tumor regression.
Zava, D. T., & McGuire, W. L. (1977) · PubMed · Cited by 28 · see citing works
Growth and therapy of mammary tumours induced by 7,12-dimethylbenzanthracene in rats.
Heise, E., & Görlich, M. (1966) · British Journal of Cancer · doi:10.1038/bjc.1966.66 · Cited by 28 · see citing works
Marchetti, B., Poulin, R., Plante, M., & Labrie, F. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90309-3 · Cited by 27 · see citing works
Self-citationSimon, W. E., PAHNKE, V. G., & Hölzel, F. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-6-1243 · Cited by 26 · see citing works
Counteraction by Prolactin of Androgen-Induced Inhibition of Mammary Tumor Growth in Rats2
QUADRI, S. K., Kledzik, G. S., & Meites, J. (1974) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/52.3.875 · Cited by 21 · see citing works
The use of androgens in the treatment of neoplastic disease
Segaloff, A. (1977) · Pharmacology & Therapeutics Part C Clinical Pharmacology and Therapeutics · doi:10.1016/s0362-5486(77)80010-1 · Cited by 20 · see citing works
The Effects of Androgens on Induced Mammary Tumours in Rats
Young, S., BAKER, R. A., & HELFENSTEIN, J. E. (1965) · British Journal of Cancer · doi:10.1038/bjc.1965.18 · Cited by 20 · see citing works
Teller, M. N., Kaufman, R. J., Stock, C. C., & Bowie, M. (1968) · PubMed · Cited by 13 · see citing works
Onset of androgen action in MCF-7 human breast cancer cells is not accompanied by receptor depletion
Shapiro, E., & Lippman, M. E. (1985) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(85)90136-0 · Cited by 10 · see citing works
Thériault, C., Poulin, R., Tremblay, S., Poirier, D., & Labrie, F. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb34323.x · Cited by 8 · see citing works
Self-citationMobbs, B. G. (1970) · Journal of Endocrinology · doi:10.1677/joe.0.0480293 · Cited by 8 · see citing works
Gordan, G. S. (1976) · Springer eBooks · doi:10.1007/978-3-642-66353-6_16 · Cited by 4 · see citing works
Anabolic-Androgenic Steroids and Experimental Mammary Tumors
Hilf, R. (1976) · Springer eBooks · doi:10.1007/978-3-642-66353-6_6 · Cited by 2 · see citing works
Bryan (1984) · doi:10.1002/1097-0142(19841201)54:11
Segaloff (1951) · doi:10.1002/1097-0142(195103)4:2
Flagged first, then by citations
Cited by
Sorted by citations
Labrie, F. (1991) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(91)90116-a · Cited by 685 · see citing works
Self-citationLabrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · see citing works
Self-citationLi, S., Yan, X., B�langer, A., & Labrie, F. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00665681 · Cited by 70 · see citing works
Self-citationAlmost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland.
Sourla, A., Martel, C., Labrie, C., & Labrie, F. (1998) · Endocrinology · doi:10.1210/endo.139.2.5762 · Cited by 49 · see citing works
Self-citationCouillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., & Labrie, F. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.772 · Cited by 38 · see citing works
Self-citationLabrie, F., Li, S., B�langer, A., C�t�, J., M�rand, Y., & Lepage, M. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665803 · Cited by 18 · see citing works
Self-citationLi, S., Lepage, M., Mérand, Y., Bélanger, A., & Labrie, F. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961245 · Cited by 14 · see citing works
Self-citation
- Authors
- Dauvois, S., Li, S., Martel, C., & Labrie, F.
- Affiliations
- Université Laval (CA)
- Venue
- Breast Cancer Research and Treatment
- Published
- 1989-12
- Volume
- 14
- Issue
- 3
- Pages
- 299-306
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2011966989
- Cited by
- 47
- References
- 53
- Citations by year
- 2023: 1 · 2022: 1 · 2018: 1 · 2014: 1 · 2012: 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- androgens, dihydrotestosterone, DMBA-induced mammary carcinoma, estradiol, androgen receptor, flutamide, androgen receptor antagonists, tumor progression, tumor regression, ovariectomized rats
- MeSH terms
- Animals, Drug Implants, Estradiol, Female, Flutamide, Mammary Neoplasms, Experimental, Organ Size, Ovariectomy, Rats, Inbred Strains, Dihydrotestosterone, Uterus, 9,10-Dimethyl-1,2-benzanthracene, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
